<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047772</url>
  </required_header>
  <id_info>
    <org_study_id>2016-807-10.1</org_study_id>
    <nct_id>NCT03047772</nct_id>
  </id_info>
  <brief_title>Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients</brief_title>
  <acronym>TEAM-AMI</acronym>
  <official_title>The Randomized Double-blind Placebo-Controlled Multi-center Clinical Trial of Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in Acute Myocardial Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuejin Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zunyi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of current stem cell transplantation therapy for myocardial infarction is limited&#xD;
      by low survival rate for stem cell. The purpose of this study is to test whether intensive&#xD;
      Atorvastatin therapy can improve the outcome of patients with impaired left ventricle&#xD;
      function after acute myocardial infarction who underwent intracoronary transfer of autologous&#xD;
      bone marrow mesenchymal stem cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major challenge to a successful stem cell therapy for myocardial infarction is the low&#xD;
      survival rate of implanted cells in the damaged tissue. Atorvastatin, an HMG-CoA reductase&#xD;
      inhibitor, has multiple biological activities independent of cholesterol-lowering action.This&#xD;
      study is performed to find out more information about the strategy with Atorvastatin therapy&#xD;
      to improve the survival of implanted cells, autologous bone marrow mesenchymal stem cells&#xD;
      transplantation. Patients between 30 and 75 years of age who receive autologous bone marrow&#xD;
      mesenchymal stem cells transplant may be eligible for this study. These patients receive&#xD;
      autologous bone marrow mesenchymal stem cells transplantation intracoronary undergoing&#xD;
      Percutaneous Coronary Intervention with regular or high dose of Atorvastatin treatment. The&#xD;
      objective evaluations will be performed at baseline and during 12 months follow-up.&#xD;
&#xD;
      Heart function tests may include the following:&#xD;
&#xD;
      Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on&#xD;
      the chest transmit information from the heart to a machine.&#xD;
&#xD;
      Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the&#xD;
      heart and examine the function of the heart chambers and valves.&#xD;
&#xD;
      Gated acquisition scan is a nuclear medicine test that uses a small amount of radioactive&#xD;
      chemical injected into a vein. A special scanner creates an image of the heart for examining&#xD;
      the beating motion of the muscle.&#xD;
&#xD;
      MRI evaluates function of the heart chambers the beating motion of the muscle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction from baseline to 12 months'</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in left ventricular ejection fraction from baseline to 12 months' by MRI</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Stem Cell Transplantation</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Phase A: Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin routine dose + placebo transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A: Low dose BMMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin routine dose + low dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A: Middle dose BMMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin routine dose + middle dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A: High dose BMMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin routine dose + high dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin routine dose + placebo transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Atorvastatin+Transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin routine dose+ Optimal dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Intensive Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin Intensive dose + placebo transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Intensive Atorvastatin+Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Routine dose of Atorvastatin therapy</description>
    <arm_group_label>Phase A: Atorvastatin</arm_group_label>
    <arm_group_label>Phase A: High dose BMMSC</arm_group_label>
    <arm_group_label>Phase A: Low dose BMMSC</arm_group_label>
    <arm_group_label>Phase A: Middle dose BMMSC</arm_group_label>
    <arm_group_label>Phase B: Atorvastatin</arm_group_label>
    <arm_group_label>Phase B: Atorvastatin+Transplantation</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Atorvastatin</intervention_name>
    <description>Intensive dose of Atorvastatin therapy</description>
    <arm_group_label>Phase B: Intensive Atorvastatin</arm_group_label>
    <arm_group_label>Phase B: Intensive Atorvastatin+Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose BMMSC</intervention_name>
    <description>Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase A: Low dose BMMSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Middle dose BMMSC</intervention_name>
    <description>Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase A: Middle dose BMMSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose BMMSC</intervention_name>
    <description>High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase A: High dose BMMSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplantation</intervention_name>
    <description>Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase B: Atorvastatin+Transplantation</arm_group_label>
    <arm_group_label>Phase B: Intensive Atorvastatin+Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with the first time ST-elevation myocardial infarction (STEMI).&#xD;
&#xD;
          2. Patients after undergoing PCI 2 to 5 days.&#xD;
&#xD;
          3. Patients without PCI but emergency coronary angiography shows the criminal coronary&#xD;
             artery recanalized.&#xD;
&#xD;
          4. Left ventricular infarction area seriously hypokinesis or no movement&#xD;
&#xD;
          5. Left ventricular ejection fraction &lt;=45% based on coronary angiography or&#xD;
             echocardiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any one of the following exclusion criteria is sufficient to disqualify a patient from the&#xD;
        study.&#xD;
&#xD;
          1. Patients without emergency PCI and the criminal coronary artery fail to be&#xD;
             recanalized.&#xD;
&#xD;
          2. Patients with non-ST-elevation myocardial infarction.&#xD;
&#xD;
          3. Patients with normal left ventricular function.&#xD;
&#xD;
          4. Patients with mechanical complications of myocardial infarction.&#xD;
&#xD;
          5. Patients with a malignant tumor.&#xD;
&#xD;
          6. Patients with infection disease.&#xD;
&#xD;
          7. Less than 6 months since last episode of stroke.&#xD;
&#xD;
          8. Patients with hematological disease (leukemia, myeloproliferative disease, or&#xD;
             myelodysplastic syndromes).&#xD;
&#xD;
          9. ALT (GPT) exceeding 100 IU/L.&#xD;
&#xD;
         10. Leukocytes less than 4,000/µL or exceeding 10,000/µL.&#xD;
&#xD;
         11. Platelets less than 100,000/µL.&#xD;
&#xD;
         12. Hemoglobin less than 10 g/dL.&#xD;
&#xD;
         13. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming&#xD;
             pregnant before the end of the study period.&#xD;
&#xD;
         14. Any other reason that the Clinical Supervisors or Clinical Researchers may have for&#xD;
             considering a case unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haiyan Qian, Doctor</last_name>
    <phone>861068314466</phone>
    <email>ahqhy712@163.com</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yuejin Yang</investigator_full_name>
    <investigator_title>Vice Dean of Fuwai hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

